BSD Medical Announces Sale of the MicroThermX® Microwave Ablation Systems in Turkey Business Wire SALT LAKE CITY -- December 5, 2013 BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, today announced that the Company has received a purchase order for multiple MicroThermX Microwave Ablation (MicroThermX) systems and antennas from its exclusive distributor in Turkey, ADA Medikal (ADA). This is the second order for multiple MicroThermX Microwave Ablation (MicroThermX) systems and antennas from ADA. ADA is a leading medical specialty distributor in Turkey with offices in the nation’s major metropolitan areas. "Turkey is estimated to be the fifth fastest emerging economy in the world and represents an exciting international market for our MicroThermX products," said Sam Maravich, Vice President of Sales and Marketing for BSD. "ADA continues to purchase additional MicroThermX systems to meet the needs of the expanding market in Turkey. Its prime location at the intersection of Europe and Asia coupled with its booming industry is making Turkey an economic leader in the Middle East. ADA represents several well-known medical device companies and sells numerous products to the same physicians targeted for the MicroThermX." About the MicroThermX ^ Microwave Ablation System The MicroThermX is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. The innovative design of the MicroThermX ^ is the first of its kind that allows delivery of higher power levels using a single generator. The MicroThermX ^ utilizes innovative synchronous phased array technology that was developed and patented by BSD to provide larger and more uniform zones of ablation during a single procedure. The MicroThermX ^ introduces into the Company’s product line innovative, high-end disposables (SynchroWave antennas) that are used in each ablation treatment and will provide a significant ongoing revenue stream. The soft tissue ablation world market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MicroThermX for ablation of soft tissue. BSD has also received CE Marking for the MicroThermX System, which allows BSD to market the MicroThermX ^ in Europe. CE Marking is also recognized in many countries outside of the EU, providing BSD the ability to market the MicroThermX ^ to a number of international markets. About BSD Medical Corporation BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy, which is delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s MicroThermX microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com. This press release may be deemed to contain forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including, among other things, the demand for the Company’s products, the ability of the Company to produce the products to meet the demand, global economic conditions and uncertainties in the geopolitical environment and other risk factors set forth in the Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking statements in this release are based on limited information currently available to the Company, which is subject to change, and the Company will not necessarily update the information. Contact: BSD Medical Corporation William (Bill) S. Barth, 801-972-5555 email@example.com fax: 801-972-5930
BSD Medical Announces Sale of the MicroThermX® Microwave Ablation Systems in Turkey
Press spacebar to pause and continue. Press esc to stop.